Payment overview · 2025
General Payments
$2,085.99
95 reported records · 24 companies
Healthcare provider profile · identity verified
Saman Lashkari, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · TARZANA, CA · NPI 1447282421
Verified facts
What the public records show
CMS Open Payments records show Saman Lashkari, M.D. received $2,085.99 in general payments during 2025 across 95 reported records.
Novartis Pharmaceuticals Corporation accounted for 11.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 316 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $232.65 | 11.2% | 10 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $189.98 | 9.1% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $181.27 | 8.7% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $179.20 | 8.6% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $173.18 | 8.3% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $139.18 | 6.7% | 7 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $126.82 | 6.1% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $125.76 | 6.0% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $105.71 | 5.1% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $88.07 | 4.2% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $80.94 | 3.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $72.73 | 3.5% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $57.76 | 2.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.22 | 2.6% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $55.18 | 2.6% | 3 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $43.39 | 2.1% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.38 | 1.3% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $25.81 | 1.2% | 1 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $24.89 | 1.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.71 | 1.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.07 | 1.0% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $19.82 | 0.9% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.44 | 0.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.83 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,085.99 | 95 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $254.12 | 11 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $189.98 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $179.20 | 8 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $126.82 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $100.39 | 5 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $92.39 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $89.87 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $88.07 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $82.57 | 7 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $79.31 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $57.76 | 2 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $55.18 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $53.88 | 2 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $46.45 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $44.82 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $43.39 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.21 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $37.30 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.99 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.99 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.69 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.02 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $25.70 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $25.66 | 1 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.71 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.71 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $24.23 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.65 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 253 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 316 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 153 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
153 | 37 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
253 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
316 | 43 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
105 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
97 | 87 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 542 | 127 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 508 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 473 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 455 | 123 |
| Trazodone Hcl | Trazodone Hcl | 437 | 107 |
| Metformin Hcl | Metformin Hcl | 339 | 98 |
| Ozempic | Semaglutide | 316 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 297 | 76 |
| Losartan Potassium | Losartan Potassium | 280 | 78 |
| Mounjaro | Tirzepatide | 253 | 45 |
| Lorazepam | Lorazepam | 252 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 247 | 64 |
| Memantine Hcl | Memantine Hcl | 222 | 49 |
| Azithromycin | Azithromycin | 208 | 152 |
| Simvastatin | Simvastatin | 190 | 43 |
| Gabapentin | Gabapentin | 183 | 49 |
| Alprazolam | Alprazolam | 177 | 42 |
| Ezetimibe | Ezetimibe | 168 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 49 |
| Synthroid | Levothyroxine Sodium | 153 | 37 |
| Famotidine | Famotidine | 148 | 34 |
| Allopurinol | Allopurinol | 140 | 35 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 135 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 131 | 37 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 128 | 92 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 122 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 19 |
| Sertraline Hcl | Sertraline Hcl | 108 | 22 |
| Montelukast Sodium | Montelukast Sodium | 107 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | 26 |
| Eliquis | Apixaban | 105 | 27 |
| Repatha Sureclick | Evolocumab | 105 | 21 |
| Lisinopril | Lisinopril | 102 | 22 |
| Methylprednisolone | Methylprednisolone | 102 | 75 |
| Omeprazole | Omeprazole | 100 | 26 |
| Donepezil Hcl | Donepezil Hcl | 99 | 20 |
| Paxlovid | Nirmatrelvir/Ritonavir | 97 | 87 |
| Furosemide | Furosemide | 94 | 32 |
| Tramadol Hcl | Tramadol Hcl | 93 | 34 |
| Potassium Chloride | Potassium Chloride | 88 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 23 |
| Atenolol | Atenolol | 83 | 18 |
| Carvedilol | Carvedilol | 82 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 82 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | 11 |
| Metformin Hcl Er | Metformin Hcl | 80 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 21 |
| Bupropion Xl | Bupropion Hcl | 67 | 14 |
| Mirtazapine | Mirtazapine | 67 | 16 |
| Valsartan | Valsartan | 66 | 16 |
| Myrbetriq | Mirabegron | 62 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 11 |
| Folic Acid | Folic Acid | 61 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 35 |
| Finasteride | Finasteride | 58 | 16 |
| Amoxicillin | Amoxicillin | 57 | 42 |
| Clonazepam | Clonazepam | 56 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 18 |
| Prednisone | Prednisone | 56 | 25 |
| Nebivolol Hcl | Nebivolol Hcl | 55 | 14 |
| Lidocaine | Lidocaine | 54 | 20 |
| Praluent Pen | Alirocumab | 54 | 17 |
| Valacyclovir | Valacyclovir Hcl | 54 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 11 |
| Levetiracetam | Levetiracetam | 53 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 53 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 18 |
| Jardiance | Empagliflozin | 52 | 13 |
| Meloxicam | Meloxicam | 52 | 16 |
| Nifedipine Er | Nifedipine | 52 | 13 |
| Pregabalin | Pregabalin | 52 | 12 |
| Estradiol | Estradiol | 51 | 17 |
| Fluconazole | Fluconazole | 51 | 29 |
| Celecoxib | Celecoxib | 50 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 14 |
| Propranolol Hcl | Propranolol Hcl | 49 | 15 |
| Xarelto | Rivaroxaban | 49 | suppressed |
| Minoxidil | Minoxidil | 48 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 34 |
| Diazepam | Diazepam | 44 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 44 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 44 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 41 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 41 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 40 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 39 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 29 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Clotrimazole | Clotrimazole | 37 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 36 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 36 | suppressed |
| Topiramate | Topiramate | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Vascepa | Icosapent Ethyl | 34 | suppressed |
| Cephalexin | Cephalexin | 32 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 32 | 12 |
| Klor-Con 10 | Potassium Chloride | 32 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 32 | 26 |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 18 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Kerendia | Finerenone | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Dotti | Estradiol | 26 | suppressed |
| Gemtesa | Vibegron | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Armour Thyroid | Thyroid,pork | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Premarin | Estrogens, Conjugated | 24 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 23 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 16 |
| Modafinil | Modafinil | 21 | suppressed |
| Progesterone | Progesterone, Micronized | 21 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 14 |
| Tavaborole | Tavaborole | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Exemestane | Exemestane | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 12 |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Epogen | Epoetin Alfa | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Cefixime | Cefixime | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 15 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 15 | 15 |
| Temazepam | Temazepam | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Topamax | Topiramate | 13 | suppressed |
| Triamterene | Triamterene | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Cymbalta | Duloxetine Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Tivicay | Dolutegravir Sodium | 12 | suppressed |
| Toprol Xl | Metoprolol Succinate | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Procrit | Epoetin Alfa | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Tiazac | Diltiazem Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,085.99 · 95 records | Novartis Pharmaceuticals Corporation | AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, EVENITY, FARXIGA, GARDASIL 9, GEMTESA, JARDIANCE, JATENZO, KISUNLA, KRYSTEXXA, Kerendia, Korlym, LEQVIO, LINZESS, LOREEV XR, Leqembi, MOUNJARO, MYFEMBREE, NURTEC ODT, NUZYRA, Ozempic, QULIPTA, REPATHA, REXULTI, SHINGRIX, SYNTHROID, TARPEYO, TRINTELLIX, UBRELVY, ULTOMIRIS, Wegovy, XIFAXAN, Xhance, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error